Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Creteil, Paris, Paris Cedex 13, Suresnes, Toulouse Cedex 9 és Vandoeuvre Les Nancy Cedex (Franciaország)Mind a 6 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 120 fő, tervezett
- Kezdés
- 2025. ápr.
- Várható befejezés
- 2029. nov.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Pulse bolus corticosteroids
- Pulse bolus corticosteroids and IVIG
- Pulse bolus corticosteroids (G5%) and IVIG (G5 %)
- A regiszteradat frissítve
- 2025. március 26.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 15 or older with fulminant myocarditis, a sudden and severe inflammation of the heart muscle causing shock.
- Életkor
- 15 years and older
- Nem
- All sexes
- A betegség stádiuma
- Fulminant myocarditis: illness started less than 1 month ago, with cardiogenic shock (heart too weak to pump enough blood, confirmed by heart ultrasound) or electrical storm (repeated dangerous heart rhythms). People must need heart support (inotropes or a temporary mechanical pump) for less than 72 hours. No blocked heart arteries or earlier heart muscle disease.
- Korábbi kezelés
- People already on corticosteroids or receiving IVIG cannot join. Heart support must have started no more than 72 hours ago.
- Biomarker vagy leletérték
- Blood cardiac troponin above twice the normal value.
A részvétel fő kizáró okai
- Pregnancy, breastfeeding, or giving birth less than 6 months ago
- Resuscitation longer than 20 minutes in total
- Earlier ischemic or dilated cardiomyopathy, or Tako-Tsubo
- Autoimmune disease or other conditions needing immune-suppressing drugs
- Myocarditis caused by anti-cancer immune checkpoint inhibitor drugs, or active severe bacterial or fungal infection
A regiszter feltételei, szó szerint
Mind a 2 feltétel megnézéseKevesebb
Ki vehet részt
- 1. Fulminant myocarditis defined by; the acute illness (<1 month from symptom onset),; hemodynamic compromise due to cardiogenic shock (confirmed by echocardiography) or electrical storm,; elevated plasma cardiac troponin > twice normal value; need for hemodynamic support (inotropes or temporary mechanical circulatory support) for less than 72 hours in the absence of an ischemic cause or other pre-existing cardiomyopathies Noticeably, a coronary angiogram should be performed in patients ≥40 years of age when myocarditis has not been proven histologically. Besides, an endomyocardial biopsy will not be mandatory to fulfill the definition of fulminant myocarditis; Signed informed consent from the patient, a close relative or surrogate or a family member or a legal representative for minor patient; Adult : According to the specifications of emergency inclusion, randomization without the close relative/surrogate consent could be performed if the patientis unable to give his/her consent and when the close relative/surrogate/family member are absent. Close relative/surrogate/family member consent will be asked as soon as possible after randomization. The patient will be asked as soon as possible to give his/her consent for the continuation of the trial when his/her condition will allow; Minor : According to the specifications of emergency inclusion, randomization could be performed when legal representative are absent. Legal representative consent will be asked as soon as possible after randomization 3. Social security registration (AME excluded)
Ki nem vehet részt
- 1. Age <15 2. Pregnancy or breastfeeding or baby delivery <6 months 3. Initiation of inotropes or temporary mechanical circulatory support >72 hours 4. Resuscitation >20 minutes (cumulative low-flow time > 20 minutes ) 5. Pre-existing ischemic or dilated cardiomyopathy or Tako-Tsubo evaluated by echocardiography; Known systemic autoimmune disorder or other conditions requiring immunosuppression 7. Patients with peripheral eosinophilia (≥1000 G/L) 8. Myocarditis associated with anti-cancer immune checkpoint inhibitor agents 9. Active severe bacterial or fungal infectious disease 10. Patient moribund on the day of randomization, SAPS II >90 11. Contraindication or allergies to corticosteroids or immunoglobulins or any components of the formulations or their excipients 12. Patients already on corticosteroids or receiving IVIG 13. Participation in another interventional study or being in the exclusion period at the end of a previous study; Patients with an uncontrolled psychotic condition Patients with known anti-IgA antibodies in line with the contraindications of methylprednisolone IV and of IVIg based products respectively
Helyszínek itt: Franciaország
- Assistance Publique Hopitaux De ParisCreteil, FranciaországToborzás még nem indult
- Assistance Publique Hopitaux de ParisParis, FranciaországToborzás még nem indult
- Assistance Publique Hopitaux De ParisParis Cedex 13, FranciaországToborzás még nem indult
- Hospital FochSuresnes, FranciaországToborzás még nem indult
- Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranciaországToborzás még nem indult
- CHRU De NancyVandoeuvre Les Nancy Cedex, FranciaországToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Fulminant myocarditis (FM) is the most severe manifestation of acute myocarditis, an acute inflammatory myocardial disease most often triggered by viral infections.
A teljes eredeti leírásKevesebb
Currently, the most accepted definition of FM requires acute illness, hemodynamic compromise due to cardiogenic shock, and need for hemodynamic support (inotropes and/or temporary mechanical circulatory support (t-MCS) in the absence of an ischemic cause or other pre-existing cardiomyopathies. Unfortunately, there is a paucity of evidence-based management strategies for this disease and the management of patients affected by FM often varies according to local experience and practice with the role of immunosuppression being the most debated issue.
Besides, due to inconsistent results obtained in several studies and frequent spontaneous recovery with supportive therapy alone, immunosuppression is largely debated in the setting of lymphocytic myocarditis (LM). Among available medications for this disease, corticosteroids are often used despite a lack of clear evidence in the context of FM. Similarly, intravenous immunoglobulin (IVIG) has both antiviral and anti-inflammatory effects on myocarditis. In adults, a recent meta-analysis based on case series showed that IVIG therapy significantly reduced in-hospital mortality, improved the left ventricular ejection fraction, and significantly increased the survival rate in patients with FM. More recently, FM among patients with COVID-19, including post-infectious multisystem inflammatory syndrome, has been reported in young adult patients. These severe forms have been successfully treated with intravenous corticosteroids and IVIG, highlighting the relevance of the systemic inflammatory response in determining cardiac injury in COVID-19, even though more evidence is needed.
A vizsgálat 3 csoportja
- Pulse bolus corticosteroids groupA vizsgált kezelés
1. 1 gram/day of methylprednisolone IV for three days followed by 1mg/kg/day IV until inotropes weaning or 7 days whatever come first. 2. Placebo of IVIG: glucose 5% 0.5g/kg/day for 4 days
Kezelés: Pulse bolus corticosteroids
- Pulse bolus corticosteroids and IVIG groupA vizsgált kezelés
1. 1 gram/day of methylprednisolone IV for three days followed by 1mg/kg/day IV until inotropes weaning or 7 days whatever come first. 2. 0.5g/kg/day IVIG for 4 days.
Kezelés: Pulse bolus corticosteroids and IVIG
- Double placebo pulse bolus corticosteroids (G5%) and IVIG (G5 %)Placebo, összehasonlításként
Kezelés: Pulse bolus corticosteroids (G5%) and IVIG (G5 %)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis: a Double-blind Randomized Controlled Adaptive Trial the CORIUM Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. március 26.